Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Files An 8-K Results of Operations and Financial ConditionItem 2.02
The following exhibits are filed as part of this Current Report:
|99.1||Press Release dated April11, 2018.|
BELLICUM PHARMACEUTICALS, INC ExhibitEX-99.1 2 d562241dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Bellicum Announces Clinical Hold Lifted on U.S. Studies of BPX-501 HOUSTON,…To view the full exhibit click
About Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. BPX-501 is an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation. The Company’s CID-based technologies include CaspaCIDe, CIDeCAR and GoCAR-T.